licensing deals

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Earendil Labs & WuXi XDC collaboration

Lucid Diligence Brief: Earendil Labs & WuXi XDC collaboration Professional…

by Timos Papagatsias

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics autoimmune deal

Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics…

by Timos Papagatsias

Lucid Diligence Brief - Tech

Lucid Diligence Brief: Unnatural Products Novartis macrocyclic peptide licensing agreement

Lucid Diligence Brief: Unnatural Products Novartis macrocyclic peptide…

by Timos Papagatsias

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Genhouse Bio and Gilead in GH31 synthetic-lethal oncology $1.5B deal

Lucid Diligence Brief: Genhouse Bio and Gilead in GH31 synthetic-lethal…

by Timos Papagatsias

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: EVOQ x Sanofi collaboration

Lucid Diligence Brief: EVOQ x Sanofi collaboration Professional audiences only.…

by Timos Papagatsias

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required
You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.